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EP-1681   
Is understanding of the risks and benefits of radiotherapy 
affected by the consenting healthcare professional? 
P. Wolfson1, T. Carter1, J. Kudhail1, T. Reynolds1, R. Moule1 
1Mount Vernon Cancer Centre, Oncology, London, United 
Kingdom  
 
Purpose/Objective: Informed consent for medical treatment 
is one of the fundamental aspects of modern medical 
treatment, the importance of which becomes even greater 
when there are potentially significant side effects to 
treatment as is the case with radiotherapy. The Quality 
Health 2012 Radiotherapy Patient Experience Survey was 
previously commissioned by the National Radiotherapy 
Implementation Group (NRIG). Following results from this, 
radiotherapy centres in the East of England region repeated 
the survey in 2013. Questions addressed issues of consent and 
understanding of treatment. 
Materials and Methods: Patients receiving radiotherapy in 
October 2013 at 7 centres in the East of England were invited 
to complete a postal patient satisfaction survey following 
their treatment. We analysed the responses to determine if 
patient understanding of the risks and benefits of treatment 
was affected by who consented them (doctor versus 
radiographer) using a chi-squared (x2) test. 
Results: 495 patients across 7 radiotherapy units in the East 
of England Cancer Network completed the postal 
questionnaire. Of these, 69% of patients reported that they 
fully understood the risks and benefits of radiotherapy, 30% 
understood this to some extent and 1% did not understand at 
all. 80% of patients were consented by a consultant 
oncologist, 7% by a doctor other than consultant and 12% 
were consented by a radiographer. 1% could not recall who 
took their consent. Data from 360 patients was available for 
analysis of individual patient responses. This showed that 
significantly more patients completely understood the risks of 
treatment when consented by an oncologist compared to a 
radiographer (x2=10.68, df=2, p<0.05). Patients were also 
more satisfied with the answers to their questions at the time 
of consent if done by an oncologist versus a radiographer 
(x2=7.9, df=2, p<0.05). 
Conclusions: These results suggest that there is increased 
understanding of the risks and benefits of radiotherapy when 
consent is taken by a senior oncology doctor compared to a 
radiographer. Patients also report higher levels of 
satisfaction with how their questions are addressed if a 
doctor versus a radiographer takes their consent. Note should 
be made of the inherent responder and reporter bias present 
in any patient survey. Furthermore, when patients report 
their understanding, responses are very difficult to validate. 
It is vital that informed consent should be taken for all 
patients by an experienced member of the multi-disciplinary 
team who feels confident to address any questions patients 
may have. 
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Purpose/Objective: Radiodermitis remains a major issue 
during breast cancer irradiation. 87% of the patients show 
acute radiodermitis in a variable degree, skin folds are the 
main location. It can cause patient discomfort, treatment 
interruptions, local control loose, and a decrease on quality 
of life. Several factors have been related with radiodermitis 
degree, some of them intrinsic (nutritional status, age, 
health status, associated diseases) and extrinsic (radiation 
dose, energy, fractionation, chemo associated). Up to know, 
no clear consensus exist about which is the best local 
moisture, as well as the timing of its use. Despite several 
local treatments have been recommended there are no 
enough studies to support such recommendations. 
Our aim is to analyse the efficacy of 7 lotions to deal with 
radiodermitis and to evaluate the patient satisfaction 
associated with its use. 
Materials and Methods: We performed a randomized study 
with 2 parallel groups in order to evaluate the efficacy of 7 
moisturizing lotions in order to avoid radiodermitis among 
irradiated breast cancer patients. Patients were evaluated 
weekly with The Radiation-Induced Skin Reaction Assessment 
Scale (RISRAS). This scale evaluates subjective patient's 
symptoms and evaluates objective skin signs by health 
professionals. Irradiation characteristics, patient 
characteristics, lotion used, total irradiation dose, cosmetic 
satisfaction, radiodermitis degree were also recorded. 
Results: 69 patients (p.) were included. Phototype skin (I, 2 
p. (2.8%); II, 16 p. (23.1%); III, 50 p. (72.4%)). Previous 
treatments: chemo 27 p. (39.13%); hormone 64 p. 
(tamoxifen, 35 p. (54.68%); aromatase inh, 29 p. (45.31%), 
antibodies, 5 p. (7.24%). Total dose up to 66 Gy, 63 p. (95%), 
7 p. (11%) also were treated with a bolus. 33% of p. need 
care with an anti-inflammatory and healing ointment, 14% of 
p. need Diprogenta. A tendency towards a wet dermatitis 
reduction was seen for lotions num 3 and 5. (p=0,31). No 
correlation between the RIS-RAS scale and cosmetic 
satisfaction was found (p=0.05), but a significant positive 
correlation was seen between cosmetic satisfaction and the 
overall cosmetic score (table 1). 
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Sum 
Ris-ras 
Cream 
1 
Cream 
2 
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3 
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4 
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5 
Cream 
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mean 8.47 9.19 8. 37 8.43 7.37 7.94 7.39 
min 6.85 6 6.5 6 6.12 6.6 6 
max 11.25 13.5 10.25 10.5 9.33 12.5 10 
sd 1.44 2.51 1.36 1.44 0.97 1.88 2.69 
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Conclusions: Our results don't show significant objective 
differences on acute radiodermitis; but significant 
differences were seen on the patient's lotion approval and 
cost. We believe that an expanded study with more patients 
is of interest.  
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Purpose/Objective:The purpose of this retrospective study 
was to evaluate the palliative role of radiotherapy (RT) in 
terms of clinical benefit in locally advanced or metastatic 
rectal cancer patients (pts).  
Materials and Methods: All pts with locally advanced disease 
and pelvic recurrence unfit for surgery or with metastatic 
disease, independently of previous treatments, were 
enrolled. The scheduled RT was 25 Gy in 5 fractions delivered 
in 5-7 days. The clinical target volume included the primary 
tumor, correspondent mesorectum, clinically involved loco-
regional lymph-nodes plus a 2 cm of margin or in case of 
pelvic recurrence the site of disease plus a 2 cm of margin. 
Three-dimensional conformal RT was used. The benefit of 
treatment was evaluated only relying on medical 
examination; in particular pain relief was assessed both by 
VAS scale and consumption of analgesic drugs. Symptom 
palliation was defined at one month after the end of RT. 
Each pt was followed every three-four months or otherwise 
the clinical information was collected by phone. A minimum 
of one month follow-up was requested for the analysis. 
Toxicity was classified according to the RTOG/EORTC scale. 
Results: From May 2007 to October 2014, 28 pts were 
treated. Pts characteristics are as follows. Gender: male 14 
(50%); female 14 (50%); stage: II 1 (3,5%), III 10 (36%), IV 8 ( 
29%), local recurrence 9 (32%); median age 79.5 years (range 
49-90); median KPS 70% (range 50-100). Initial presenting 
symptoms were: bleeding in 24 (85,7%); pain in 9 (32,1%); 
rectal tenesmus in 7 (25%); patter change in 7 (25%); 
mucorrea in 5 pts (17,8%). Among the 28 pts, 7 (25 %) 
underwent chemotherapy as first treatment and received RT 
due to local progression of the disease; of these five (71,4%) 
had stage IV and two (28,6%) local recurrence. All pts 
completed the scheduled treatment. Overall, twenty-four 
(85,6%) pts responded to RT; in particular 18 (64,2%) 
experienced complete remission, 6 (21,4%) significant 
improvement, while 4 (14,4%) no change of symptoms. 
Regarding response obtained according to type of symptom, 
bleeding disappeared in 83% of pts, pain relief was obtained 
in 89% and rectal tenesmus in 92,8%. Symptoms relapse 
occurred in only 4 (14%) pts, as bleeding (3 cases) and rectal 
tenesmus (1 case). RT was well tolerated; only one pt 
developed acute urinary retention that required temporary 
application of bladder catheter. Two pts with wide vaginal 
involvement, as a consequence of response to treatment, 
experienced a recto-vaginal fistula. Median time to symptom 
relapse was 8 months (range 2-71). Median survival after RT 
was 8.5 months (range 2-71). Twenty-two (77%) pts died, but 
only 5 (15%) for local disease progression.  
Conclusions: Our results suggest that short-course RT can be 
feasible and effective in this subset of rectal cancer pts, both 
in terms of symptoms relief rate and duration of clinical 
benefit. 
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Purpose/Objective: Malignant spinal cord compression 
(MSCC) is an oncology emergency that requires prompt 
diagnosis and management to minimise morbidity and 
improve patient outcome. In order to minimise delay in 
diagnosis and initiation of treatment a malignant spinal cord 
pathway has been devised and implemented throughout the 
cancer network. This prospective audit aimed to identify the 
proportion of patients meeting the recommendations of the 
pathway-MRI(or CT if contraindicated) within 24 hours of 
presentation with suspected MSCC; treatment decision 
(surgery or RT) within 24hours of diagnosis of MSCC; in 
patients in whom RT is recommended treatment to 
commence within 24hours of MRI. 
Materials and Methods: MSCC cases were identified from 
requests for whole spine MRI in patients with suspected 
